Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer
- The P-III (SKYSCRAPER-01) study evaluating tiragolumab + Tecentriq vs Tecentriq alone in a ratio (1:1) in 534 patients with PD-L1-high LA or metastatic NSCLC
- The study failed to meet its co-primary EPs of PFS & the other co-primary EPs of OS were immature, numerical improvement was identified in both co-primary EPs. The results demonstrated that the therapy was well-tolerated and no new safety signals were reported
- The program continues to advance the therapy for multiple clinical trials & expand into earlier stages of the disease. The company focuses to develop novel therapeutic options for malignancies that are advanced and difficult to treat in patients with a high unmet medical needs
Ref: Roche | Image: Roche
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.